See more : PT Delta Djakarta Tbk (DLTA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Tekla Life Sciences Investors (HQL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tekla Life Sciences Investors, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Bauba Resources Limited (BAU.JO) Income Statement Analysis – Financial Results
- Malachite Innovations, Inc. (MLCT) Income Statement Analysis – Financial Results
- Iron Horse Acquisitions Corp. Unit (IROHU) Income Statement Analysis – Financial Results
- Hagihara Industries Inc. (7856.T) Income Statement Analysis – Financial Results
- Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) Income Statement Analysis – Financial Results
Tekla Life Sciences Investors (HQL)
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.69M | 23.52M | -103.25M | 65.69M | 124.08M | -69.34M | 29.82M | 69.81M | 6.29M | 1.32M | 876.79K | 516.76K | 2.14M | 570.00K | 1.82M | 460.00K | 1.67M | 2.88M | 2.30M | 890.00K | 320.00K | 610.00K | 940.00K | 1.77M | 140.00K | 320.00K | 420.00K |
| Cost of Revenue | 0.00 | 5.24M | 5.55M | 6.08M | 5.21M | 5.00M | 4.77M | 4.61M | 4.95M | 5.65M | 4.14M | 3.10M | 2.48M | 3.02M | 2.99M | 2.85M | 3.76M | 3.62M | 2.93M | 2.81M | 2.78M | 2.44M | 2.86M | 3.26M | 1.64M | 1.63M | 1.60M |
| Gross Profit | 86.69M | 18.28M | -108.80M | 59.61M | 118.88M | -74.35M | 25.05M | 65.20M | 1.34M | -4.33M | -3.26M | -2.58M | -335.50K | -2.45M | -1.17M | -2.39M | -2.09M | -740.00K | -630.00K | -1.92M | -2.46M | -1.83M | -1.92M | -1.49M | -1.50M | -1.31M | -1.18M |
| Gross Profit Ratio | 100.00% | 77.71% | 105.37% | 90.75% | 95.80% | 107.22% | 84.00% | 93.40% | 21.34% | -327.02% | -372.18% | -499.89% | -15.64% | -429.82% | -64.29% | -519.57% | -125.15% | -25.69% | -27.39% | -215.73% | -768.75% | -300.00% | -204.26% | -84.18% | -1,071.43% | -409.38% | -280.95% |
| Research & Development | 0.00 | 0.00 | -3.28 | 1.43 | 3.15 | -1.84 | 0.80 | 1.46 | -1.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | 5.23M | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | -1.89 | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Other Expenses | 85.35M | 22.62M | 275.97K | 313.69K | 278.66K | 259.76K | 466.64K | 423.33K | 20.74M | 143.44K | 130.00K | 150.00K | 200.00K | 200.00K | 160.00K | 170.00K | 140.00K | 250.00K | 160.00K | 150.00K | 80.00K | 60.00K | 120.00K | 110.00K | 10.00K | 40.00K | 290.00K |
| Operating Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 1.16M | 1.26M | 13.35M | 39.18M | 88.39M | 84.13M | 75.49M | 1.35M | 790.00K | 760.00K | 820.00K | 970.00K | 710.00K | 660.00K | 610.00K | 510.00K | 590.00K | 450.00K | 240.00K | 230.00K | 290.00K |
| Cost & Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 5.59M | 5.56M | 1.34M | 39.18M | 88.39M | 84.13M | 75.49M | 4.37M | 3.78M | 3.61M | 4.58M | 4.59M | 3.64M | 3.47M | 3.39M | 2.95M | 3.45M | 3.71M | 1.88M | 1.86M | 1.89M |
| Interest Income | 1.04M | 204.45K | 50.09K | 0.00 | 164.80K | 216.70K | 90.71K | 90.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.27M | 72.43M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 0.00 | 27.60M | 2.99M | 4.14M | 2.11M | 2.88M | 3.61M | 3.88M | 3.79M | 4.72M | 3.77M | 3.17M | 1.28M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| EBITDA | 0.00 | 22.35M | -104.61M | 64.54M | 123.06M | -70.47M | 28.67M | 68.56M | 0.00 | 0.00 | 0.00 | 0.00 | 78.91M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| EBITDA Ratio | 0.00% | 95.03% | 101.31% | 98.24% | 99.17% | 101.64% | 204.33% | 201.96% | 289.30% | 3,419.13% | 10,610.66% | 16,993.50% | 3,679.80% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Operating Income | 0.00 | -5.24M | -104.60M | 64.53M | 123.05M | -70.48M | -3.61M | -3.88M | -3.79M | -4.72M | -3.77M | -3.17M | -1.28M | -3.80M | -1.96M | -3.15M | -2.92M | -1.71M | -1.34M | -2.59M | -3.07M | -2.34M | -2.52M | -1.94M | -1.75M | -1.53M | -1.47M |
| Operating Income Ratio | 0.00% | -22.29% | 101.31% | 98.24% | 99.17% | 101.64% | -12.10% | -5.56% | -60.25% | -357.04% | -429.50% | -613.43% | -59.85% | -666.67% | -107.69% | -684.78% | -174.85% | -59.38% | -58.26% | -291.01% | -959.38% | -383.61% | -268.09% | -109.60% | -1,250.00% | -478.13% | -350.00% |
| Total Other Income/Expenses | 85.30M | 27.60M | -101.61M | 6.08M | 5.21M | -67.60M | 32.61M | 72.74M | -8.12M | 45.22M | 93.03M | 87.82M | 78.91M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| Income Before Tax | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Income Before Tax Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.33% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Income Tax Expense | 0.00 | 0.00 | -2.99M | -4.15M | -2.13M | -2.88M | 1.00 | 3.00 | 26.32M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Net Income Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.30% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| EPS | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | 3.21 | 1.00 | 2.06 | 4.70 | 5.65 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| EPS Diluted | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.23 | 3.21 | 20.74M | 2.06 | 4.70 | 5.64 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| Weighted Avg Shares Out | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 22.41M | 21.36M | -11.91M | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
| Weighted Avg Shares Out (Dil) | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 23.30M | 21.36M | -0.57 | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
Wells Fargo & Company MN Increases Stock Position in Tekla Life Sciences Investors (NYSE:HQL)
Wells Fargo & Company MN grew its stake in shares of Tekla Life Sciences Investors (NYSE:HQL) by 3.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 255,156 shares of...
Royal Bank of Canada Boosts Stock Position in Tekla Healthcare Investors (NYSE:HQH)
Royal Bank of Canada raised its position in shares of Tekla Healthcare Investors (NYSE:HQH) by 0.2% during the 1st quarter, Holdings Channel reports. The firm owned 461,726 shares of the financial services provider’s stock after buying an additional 1,110 shares...
The Reopening Killed The V-Shaped Recovery
This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ
Geode Capital Management LLC Grows Stock Holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Geode Capital Management LLC raised its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 16.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,740,512 shares of...
5 Best CEFs To Buy This Month (June 2020)
During the last few months, most closed-end funds have been hit hard. Moreover, their recovery had lagged the broader market, but more recently, they have been
MML Investors Services LLC Purchases 1,673 Shares of Tekla Healthcare Investors (NYSE:HQH)
MML Investors Services LLC boosted its position in shares of Tekla Healthcare Investors (NYSE:HQH) by 10.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned...
Rockefeller Capital Management L.P. Acquires New Holdings in Tekla Healthcare Investors (NYSE:HQH)
Rockefeller Capital Management L.P. bought a new stake in Tekla Healthcare Investors (NYSE:HQH) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,613 shares of the financial services provider’s stock, valued...
Tekla World Healthcare Fund Paid Distribution
On May 29, 2020, Tekla World Healthcare Fund paid a monthly distribution of $0.1167 per share. It is currently estimated that this distribution is der
Source: https://incomestatements.info
Category: Stock Reports